Biote Reports Third Quarter 2026 Financial Results
Business Wire•04/11/2026•16:11 ET
2
Key Highlights
- ➤Q3 revenue $43.3 million, down 9.6% year over year
- ➤Q3 procedure revenue declined 15.1% to $28.9 million
- ➤Q3 net income fell to $0.6 million from $9.2 million
- ➤Q3 Adjusted EBITDA dropped to $5.1 million from $12.9 million
- ➤Biote maintains 2026 guidance: revenue above $175 million, Adjusted EBITDA above $25 million
Expert Statements
Bob Peterson, Interim Chief Executive Officer of Biote
“While a recent improvement in procedure volume provides early evidence of stabilization in underlying demand, our return to growth is progressing more slowly than anticipated”
Bob Peterson, Interim Chief Executive Officer of Biote
“Our immediate priorities are to improve sales productivity and strengthen engagement with our trained practitioners as we work toward a return to revenue growth.”
Bob Peterson, Interim Chief Executive Officer of Biote
“As part of this increased engagement, our Chief Medical Officer, Dr. Komal Bajaj, who joined Biote in June, is working closely with practitioners to strengthen clinical excellence across our network.”
Bob Peterson, Interim Chief Executive Officer of Biote
“Her efforts are focused on helping practitioners apply Biote’s clinical education and support within their practices, reinforcing the quality and consistency of care.”
Bob Peterson, Interim Chief Executive Officer of Biote
“Enhancing our clinical resources remains essential to deepening our practitioner relationships and supporting our long-term strategy.”
Bob Peterson, Interim Chief Executive Officer of Biote
“Our strategic initiatives remain central to strengthening the business, and the foundational work completed over the past year provides a basis for improvement.”
Bob Peterson, Interim Chief Executive Officer of Biote
“As we move forward, we remain focused on enhancing the practitioner experience, increasing sales productivity, and supporting a return to growth.”
Bob Peterson, Interim Chief Executive Officer of Biote
“We recognize that our progress will ultimately be measured by our ability to deliver stronger, more consistent financial results.”
* Net income of $0.6 million and diluted earnings per share attributable to biote Corp. stockholders of $0.01
Adjusted EBITDA(1) of $5.1 million and Adjusted EBITDA margin(1) of 11.7%
Get started
Create a free account to read the full story.